Roche licenses Rona's ALK7 RNAi obesity candidate for up to $100m near term

Roche has taken an exclusive worldwide licence to an RNAi drug candidate from Rona Therapeutics that silences ALK7, a receptor found mainly in fat cells, the two companies announced on 13 October 2026 ¹. Rona receives up to $100M in upfront and near-term milestone payments ¹.

The terms and the asset

Beyond the near-term money, Rona can earn up to $1.06 billion in development, regulatory and commercial milestones, plus tiered royalties on global net sales ¹. Fierce Biotech puts the total value of the deal at about $1.2 billion ².

The candidate uses Rona's own platform for delivering RNAi outside the liver ¹. Neither its codename nor its stage of development was disclosed ². Rona's public pipeline lists two preclinical obesity programmes against undisclosed targets, and none of its assets with known targets act on ALK7 ².

ALK7 is encoded by the ACVR1C gene and sits in the TGF-beta receptor superfamily ¹. Rona says human genetic studies link reduced ALK7 activity to a healthier fat distribution and metabolic profile ¹. Fierce Biotech adds that ALK7 variants have been tied to lower waist-to-hip ratios, and that mice with inactivated ALK7 signalling resist obesity ².

The commercial case rests on mechanism. Incretin drugs mainly act in the brain to cut appetite and energy intake. Silencing ALK7 instead works on fat tissue directly, with the aim of shrinking visceral and other ectopic fat while keeping lean mass ¹. Rona presents this as an approach that could be used alone or alongside established obesity treatments such as GLP-1 receptor agonists ¹². Rona chief executive Stella Shi said the field needs "mechanisms that can improve the quality and durability of weight loss" ¹.

What it means for the market

The deal puts Roche into a crowded early race. Fierce Biotech lists Alnylam, Arrowhead Pharmaceuticals, GSK and Novo as already working on the target ². Arrowhead reported in January a 14.1% placebo-adjusted reduction in visceral fat eight weeks after a single dose of its candidate, the first human evidence for the mechanism ². Alnylam started a clinical trial of its ALK7 candidate in March and has phase 1 data on its roadmap for the second half of 2026 ². GSK paid China's SiranBio $55 million for a phase 1 ALK7 candidate in May, and Novo said at its investor day last month that it has several assets aimed at the target, with the most advanced due to enter the clinic this year ².

For Roche the licence fits a strategy built largely on acquisitions and partnerships. Fierce Biotech reports that the company wants to rank among the three leading obesity companies and entered the field through its $2.7 billion purchase of Carmot Therapeutics, adding assets through deals with Hanmi Pharm and Zealand Pharma ². Results have been mixed so far: Roche has dropped one asset and is working to answer doubts about enicepatide and petrelintide ².

The structure also says something about pricing. With near-term cash capped at $100M against more than $1 billion in back-ended milestones, Rona carries most of the development risk until the asset proves itself in people ¹. The deal adds to a run of Western companies sourcing obesity assets from Chinese biotechs, a trend Fierce Biotech flags through GSK's SiranBio purchase and its own description of Rona as a Chinese company ². Rona's release is datelined Santa Barbara, California ¹.

Caveats

The companies have published no clinical data on the licensed candidate, and its development stage is undisclosed ². Human evidence for ALK7 as an obesity target so far rests on Arrowhead's early single-dose result ². Rona's release contains forward-looking statements that it says may differ materially from actual results ¹. The next public test for the target is Alnylam's phase 1 readout, which the company has scheduled for the second half of 2026 ².